Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications

CompletedOBSERVATIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
AsthmaObesity
Interventions
DRUG

Beclomethasone dipropionate HFA

Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation

DRUG

Tiotropium bromide

Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation

DRUG

Salmeterol xinafoate

Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation

Trial Locations (10)

10032

Columbia University Medical Center, New York

27157

Wake Forest University Health Sciences, Winston-Salem

27710

Duke University Medical Center, Durham

53706

University of Wisconsin, Madison

63130

Washington University, St Louis

77555

University of Texas Medical Branch, Galveston

80206

National Jewish Medical & Research Center, Denver

92093

University of California, San Diego, San Diego

94143

University of California, San Francisco, San Francisco

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

National Jewish Health

OTHER

NCT00557180 - Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications | Biotech Hunter | Biotech Hunter